調査レポートカテゴリー： Infiniti Research TechNavio, 世界, 医療/バイオ

Global Rheumatoid Arthritis Drugs Market 2014-2018

世界の関節リウマチ（RA）治療薬市場（2014-2018）

◆タイトル：Global Rheumatoid Arthritis Drugs Market 2014-2018
◆商品コード：IRTNTR3808
◆調査・発行会社：Technavio (Infiniti Research Ltd.)
◆発行日：2014年7月14日
◆ページ数：94
◆資料形式：pdf / 英語
◆納品方法：Eメール
◆調査対象地域：グローバル
◆販売価格オプション（消費税別）
Single UserUSD2,500 ⇒換算￥282,500見積依頼/購入/質問フォーム
Five UserUSD2,800 ⇒換算￥316,400見積依頼/購入/質問フォーム
Enterprise License（社内共有可）USD3,500 ⇒換算￥395,500見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※商品の納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。（振込先：三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。（但し、対応範囲は弊社で判断）
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

 【資料の概要】

本調査レポートでは、"世界の関節リウマチ（RA）治療薬市場（2014-2018）"について調査・分析し、エグゼクティブサマリー、市場概観、市場規模及び予測、カテゴリー別分析、主要地域別分析、市場シェア、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業（ベンダー）分析等の情報をお届けいたします。

About Rheumatoid Arthritis
RA is a chronic disease that leads to inflammation and pain in the human body’s joints such as wrists, fingers, knees, feet, and ankles. In addition, it causes inflammation of the tissues that surround the joints and in other organs. The symptoms of RA begin slowly, usually just mild pain around the joints coupled with stiffness and fatigue, and in the later stages it causes inflammation of the joints. It can occur at any age, even in children, which is called juvenile arthritis. The disease is three times more common in women than in men. Genetic and environmental elements are known to contribute in the development of RA.
TechNavio’s analysts forecast the Global Rheumatoid Arthritis Drugs market will grow at a CAGR of 4.09 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Rheumatoid Arthritis Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of RA that are available in the market. The Global Rheumatoid Arthritis Drugs market can be divided into two segments: Symptomatic and DMARDs.
TechNavio’s report, the Global Rheumatoid Arthritis Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Rheumatoid Arthritis Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• EMEA
• APAC
Key Vendors
• AbbVie Inc.
• Amgen Inc.
• Bristol-Myers Squibb Co.
• F. Hoffmann-La Roche Ltd.
• Janssen Pharmaceuticals Inc.
• Pfizer Inc.
Other Prominent Vendors

• AB Science SA
• Astellas Pharma Inc.
• AstraZeneca plc
• Biogen Idec Inc.
• Boehringer Ingelheim GmbH
• Celgene Corp.
• Daiichi Sankyo Co. Ltd.
• Eli Lilly & Co.
• GE Healthcare Co.
• Genmab A/S
• GSK plc
• Incyte Corp.
• Merck & Co. Inc.
• Mitsubishi Tanabe Pharma Corp.
• Novartis AG
• Novo Nordisk A/S
• Rigel Pharmaceuticals Inc.
• Sanofi
• Takeda Pharmaceutical Co. Ltd.
• UCB SA
• Vertex Pharmaceuticals Inc.
Key Market Driver
• Increasing Aging Population
• For a full, detailed list, view our report.
Key Market Challenge
• High Cost of RA Treatment
• For a full, detailed list, view our report.
Key Market Trend
• Increase in R&D Activities
• For a full, detailed list, view our report.
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
03.2.1 Product Profiles
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
07. Competitive Assessment of Top Drugs
08. Five Forces Analysis
09. Market Segmentation by Category
10. Geographical Segmentation
11. Buying Criteria
12. Rate of Incidence and Prevalence
12.1.1 US
12.1.2 UK
12.1.3 Asia
13. Pipeline Snapshot
14. Market Growth Drivers
15. Drivers and their Impact
16. Market Challenges
17. Impact of Drivers and Challenges
18. Market Trends
19. Trends and their Impact
20. Vendor Landscape
20.1 Competitive Scenario
20.1.1 Key News
20.1.2 Mergers and Acquisitions
20.2 Market Share Analysis 2013
20.3 Other Prominent Vendors
21. Key Vendor Analysis
21.1 AbbVie
21.1.1 Key Facts
21.1.2 Business Description
21.1.3 Product Segmentation
21.1.4 Revenue by Product Line
21.1.5 Revenue Comparison 2012 and 2013
21.1.6 Revenue by Geographical Segmentation
21.1.7 Business Strategy
21.1.8 Key Developments
21.1.9 SWOT Analysis
21.1.10 Strengths
21.1.11 Weaknesses
21.1.12 Opportunities
21.1.13 Threats
21.2 Amgen
21.2.1 Key Facts
21.2.2 Business Overview
21.2.3 Product Segmentation by Revenue 2013
21.2.4 Geographical Segmentation by Revenue 2013
21.2.5 Business Strategy
21.2.6 Key Information
21.2.7 SWOT Analysis
21.2.8 Strengths
21.2.9 Weaknesses
21.2.10 Opportunities
21.2.11 Threats
21.3 Bristol-Myers Squibb
21.3.1 Key Facts
21.3.2 Business Overview
21.3.3 Product Segmentation
21.3.4 Sales by Geography
21.3.5 Business Strategy
21.3.6 Key Information
21.3.7 SWOT Analysis
21.3.8 Strengths
21.3.9 Weaknesses
21.3.10 Opportunities
21.3.11 Threats
21.4 F. Hoffmann La Roche
21.4.1 Key Facts
21.4.2 Business Overview
21.4.3 Business Segmentation
21.4.4 Business Segmentation by Revenue 2012 and 2013
21.4.5 Sales by Geography
21.4.6 Business Strategy
21.4.7 Key Information
21.4.8 SWOT Analysis
21.4.9 Strengths
21.4.10 Weaknesses
21.4.11 Opportunities
21.4.12 Threats
21.5 Janssen Pharmaceuticals
21.5.1 Key Facts
21.5.2 Business Overview
21.5.3 Business Segmentation
21.5.4 Business Strategy
21.5.5 Key Developments
21.5.6 SWOT Analysis
21.5.7 Strengths
21.5.8 Weaknesses
21.5.9 Opportunities
21.5.10 Threats
21.6 Pfizer
21.6.1 Key Facts
21.6.2 Business Overview
21.6.3 Business Segmentation by Revenue 2013
21.6.4 Business Segmentation by Revenue 2012 and 2013
21.6.5 Sales by Geography
21.6.6 Business Strategy
21.6.7 Key Developments
21.6.8 SWOT Analysis
21.6.9 Strengths
21.6.10 Weaknesses
21.6.11 Opportunities
21.6.12 Threats
22. Other Reports in this Series

List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Rheumatoid Arthritis Drugs Market 2013-2018 (US$ billion)
Exhibit 3: Competitive Assessment of Top RA Drugs
Exhibit 4: Revenue Share of RA Drugs by Key Vendors 2013
Exhibit 5: Global Rheumatoid Arthritis Drugs Market Segmentation by Treatment Approach
Exhibit 6: Global Rheumatoid Arthritis Drugs Market Segmentation by Treatment Approach 2013
Exhibit 7: Global Rheumatoid Arthritis Drugs Market by Geographical Segmentation 2013
Exhibit 8: Global Rheumatoid Arthritis Drugs Market Share Analysis 2013
Exhibit 9: AbbVie Inc.: Product Segmentation
Exhibit 10: AbbVie Inc.: Revenue by Product Line 2013
Exhibit 11: AbbVie Inc.: Revenue Comparison by Product Line 2012 and 2013 (US$ billion)
Exhibit 12: AbbVie Inc.: Revenue by Geographical Segmentation 2013
Exhibit 13: Amgen: Product Segmentation by Revenue 2013
Exhibit 14: Amgen: Geographical Segmentation by Revenue 2013
Exhibit 15: Bristol-Myers Squibb Co.: Product Segmentation (Based on Therapeutic Areas)
Exhibit 16: Bristol-Myers Squibb Co.: Sales by Geography 2013
Exhibit 17: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
Exhibit 18: F. Hoffmann-La Roche Ltd: Business Segmentation by Revenue 2012 and 2013
Exhibit 19: F. Hoffmann-La Roche Ltd: Sales by Geography 2013 (Pharmaceuticals Division)
Exhibit 20: F. Hoffmann-La Roche Ltd: Sales by Geography 2013 (Diagnostics Division)
Exhibit 21: Janssen Pharmaceuticals Inc.: Product Segmentation 2013
Exhibit 22: Pfizer Inc.: Business Segmentation by Revenue 2013
Exhibit 23: Pfizer Inc.: Business Segmentation by Revenue 2012 and 2013
Exhibit 24: Pfizer Inc.: Sales by Geography 2013



【掲載企業】

AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Janssen Pharmaceuticals Inc., Pfizer Inc. , AB Science SA, Astellas Pharma Inc., AstraZeneca plc, Biogen Idec Inc., Boehringer Ingelheim GmbH, Celgene Corp., Daiichi Sankyo Co. Ltd., Eli Lilly & Co., GE Healthcare Co., Genmab A/S, GSK plc, Incyte Corp., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corp., Novartis AG, Novo Nordisk A/S, Rigel Pharmaceuticals Inc., Sanofi, Takeda Pharmaceutical Co. Ltd., UCB SA, Vertex Pharmaceuticals Inc.

【資料のキーワード】

関節リウマチ、治療、医薬品

【調査方法】

一次資料による調査（業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など）及び二次資料による調査（Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど）

★調査レポート[世界の関節リウマチ（RA）治療薬市場（2014-2018）] (Global Rheumatoid Arthritis Drugs Market 2014-2018 / IRTNTR3808)販売に関する免責事項
[世界の関節リウマチ（RA）治療薬市場（2014-2018）] (Global Rheumatoid Arthritis Drugs Market 2014-2018 / IRTNTR3808)についてEメールでお問い合わせ
◆関連調査資料◆
  • ヨーロッパのてんかん（Epilepsy）治療薬市場
    IRTNTR7242 / Technavio / 2015年9月30日 / 当調査レポートでは、ヨーロッパのてんかん（Epilepsy）治療薬市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、ヨーロッパのてんかん（Epilepsy）治療薬市場規模及び予測、市場シェア、市場の成長要因、市場の課題、市場動向、競争状況、主要企業（ベンダー）分析などの情報をお届けいたします。...About epilepsy Epilepsy refers to a spectrum of brain disorders manifested by benign to severe, disabling, and life-threatening symptoms. It is caused by factors ranging from brain malformations and tumors to meningitis, high-risk pregnancies, and trauma during birth. When the underlying cause of the disease is unidentified, as is witnessed in the majority of cases, it is known as idiopathic epilepsy. An imbalance between the inhibitory and excitatory signals of the brain, leading to a sudden onset of excitation, results in seizures. Technavio's analysts forecast the epilepsy drugs market in Europe to grow at a CAGR of 3.22% over the...
  • 欧州の嚢胞性線維症（CF症）治療薬市場
    IRTNTR5271 / Technavio / 2015年2月18日 / 当調査レポートでは、欧州の嚢胞性線維症（CF症）治療薬市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、欧州の嚢胞性線維症（CF症）治療薬市場規模及び予測、市場シェア、主要国別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業（ベンダー）分析などの情報をお届けいたします。...About Cystic Fibrosis Cystic fibrosis, also known as mucoviscidosis, is a genetically inherited disease. The primary symptoms of cystic fibrosis include high salt content in the sweat, breathing difficulties, secretion of abnormally viscous mucus, respiratory complications, difficulties related to digestion, and growth anomalies. Cystic fibrosis is one of the most common genetic disorders observed in Caucasian children. Rare diseases are those that affect less than 5 patients per 10,000, as defined in the EU by Rare Disease UK. Cystic fibrosis is therefore classified under rare diseases. The incidence of cystic fibrosis varies between populations. It is significantly less common in...
  • 米国のてんかん（Epilepsy）治療薬市場
    IRTNTR5028 / Technavio / 2015年1月7日 / 当調査レポートでは、米国のてんかん（Epilepsy）治療薬市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、米国のてんかん（Epilepsy）治療薬市場規模及び予測、市場シェア、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業（ベンダー）分析などの情報をお届けいたします。...About Epilepsy Epilepsy is a spectrum of brain disorders varying from benign to severe, disabling, and life-threatening symptoms. It is caused by various factors ranging from brain malformations and tumors to meningitis, high-risk pregnancies, and birth trauma. However, when the underlying cause of the disease is unidentified, as in the majority of the cases, it is known as idiopathic epilepsy. Epilepsy is characterized by repeated occurrence of generalized or focal seizures. An imbalance between the inhibitory and excitatory signals of the brain, leading to a sudden onset of excitation, results in seizures. Occurrence of two or more unprovoked seizures is...
  • アジア太平洋のてんかん（Epilepsy）治療薬市場
    IRTNTR4895 / Technavio / 2014年12月31日 / 当調査レポートでは、アジア太平洋のてんかん（Epilepsy）治療薬市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、アジア太平洋のてんかん（Epilepsy）治療薬市場規模及び予測、市場シェア、主要国別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業（ベンダー）分析などの情報をお届けいたします。...About Epilepsy Therapeutics Epilepsy is a spectrum of brain disorders varying from benign to severe, disabling, and life-threatening symptoms. It is caused by various factors ranging from brain malformations and tumors to meningitis, high-risk pregnancies, and birth trauma. However, when the underlying cause of the disease is unidentified, as in the majority of the cases, it is known as idiopathic epilepsy. Epilepsy is characterized by repeated occurrence of generalized or focal seizures. An imbalance between the inhibitory and excitatory signals of the brain, leading to a sudden onset of excitation, results in seizures. Occurrence of two or more unprovoked seizures...
  • 世界の早漏症(PE)治療薬市場
    IRTNTR4315 / Technavio / 2014年10月1日 / ...About Premature Ejaculation Premature ejaculation is a common sexual dysfunction in men, which is characterized by early discharge of semen. Premature ejaculation can be diagnosed through IELT, which is the average time taken by a man to ejaculate during sexual intercourse. There are two types of premature ejaculation: Primary premature ejaculation and secondary premature ejaculation. TechNavio's analysts forecast the Global Premature Ejaculation market to grow at a CAGR of 10.20 percent over the period 2013-2018. Covered in this Report This report covers the present scenario and the growth prospects of the Global Premature Ejaculation market for the period 2014–2018. To...
  • 世界の膵癌（膵臓癌）治療薬市場：化学療法、標的治療
    IRTNTR4314 / Technavio / 2014年10月1日 / ...About Pancreatic Cancer Pancreatic cancer is a malignant cells form in the tissues of pancreas. Based on the initiation, pancreatic cancer can be classified into exocrine pancreatic cancer and endocrine pancreatic cancer. When pancreatic cancer cells spread from the pancreas to other parts of the body, it is known as metastatic pancreatic order. The incidence and mortality rate of pancreatic cancer is higher in men than in women. SEER estimates that there were 46,420 new pancreatic cancer cases recorded in the US in 2014. It also estimated that 39,590 deaths occurred in the US in 2014 as a result of...
  • 世界のED（勃起不全）治療薬市場
    IRTNTR4092 / Technavio / 2014年9月10日 / ...About Erectile Dysfunction Drugs A man's failure to sustain an erection that is adequate enough for sexual activity is known as erectile dysfunction. It also refers to the inconsistency to do so, or the inability to endure it for an extended period. Erectile dysfunction can be due to a number of reasons including aging, high blood pressure, diabetes mellitus, depression, smoking, nerve or spinal cord damage, alcoholism, and low testosterone levels. Treatments for erectile dysfunction include adopting a healthy lifestyle, oral phosphodiesterase type 5 (PDE5) inhibitors, vacuum devices, and surgery. Erectile dysfunction affects the quality of life and leads to...
  • 世界の多発性硬化症治療薬市場（2014-2018）
    IRTNTR3981 / Technavio / 2014年8月20日 / ...About Multiple Sclerosis and Disease Types Multiple sclerosis is a chronic, inflammatory medical condition that results in demyelination, axonal transection, and neurodegeneration. The myelin sheath is damaged because of an abnormal response by the immune system, which targets neurons within the central nervous system (CNS). It is a potentially debilitating disease in which the damage of the myelin sheath causes disruption in the communication and coordination functions of the body. The symptoms of multiple sclerosis differ widely, subject to the extent of damage and the number of neurons affected. Some of the symptoms observed in a patient with multiple sclerosis...
  • 世界の消化性潰瘍治療薬市場（2014-2018）
    IRTNTR4006 / Technavio / 2014年8月13日 / ...About Peptic Ulcer and Drugs Used for the Treatment A peptic ulcer is an open lesion that develops on the mucosal lining of the stomach and small intestine because of the caustic effect of the gastric acids and enzymes in these organs. The symptoms of peptic ulcers are pain in the abdomen, nausea, vomiting, and bloated stomach. The major symptoms include bleeding from the ulcer, which can be life-threatening. It is detected by bloody and sticky stools, often black in color. Peptic ulcers are caused mainly by a Helicobacter pylori infection followed by the overuse of OTC NSAIDs such as...
  • 世界の希少難病治療薬（Orphan Drugs）市場動向（2014～2018）
    IRTNTR3181 / Technavio / 2014年1月17日 / ...TechNavio's analysts forecast the Global Orphan Drugs market to grow at a CAGR of 5.67 percent over the period 2013-2018. One of the key factors contributing to this market growth is the shorter development timelines. The Global Orphan Drugs market has also been witnessing the growing awareness of orphan drugs. However, the high cost of drug development could pose a challenge to the growth of this market. TechNavio's report, the Global Orphan Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions;...

    • ◆H&Iグローバルリサーチ株式会社のお客様（例）◆